ES2671434T3 - Antagonistas de Kv1.3 y métodos de uso - Google Patents

Antagonistas de Kv1.3 y métodos de uso Download PDF

Info

Publication number
ES2671434T3
ES2671434T3 ES14743871T ES14743871T ES2671434T3 ES 2671434 T3 ES2671434 T3 ES 2671434T3 ES 14743871 T ES14743871 T ES 14743871T ES 14743871 T ES14743871 T ES 14743871T ES 2671434 T3 ES2671434 T3 ES 2671434T3
Authority
ES
Spain
Prior art keywords
antagonists
methods
amino acid
acid sequence
isoleucine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14743871T
Other languages
English (en)
Inventor
Ellen Chi
Wilson EDWARDS
Chichi Huang
Wai-Ping Leung
Ronald Swanson
Alan Wickenden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Application granted granted Critical
Publication of ES2671434T3 publication Critical patent/ES2671434T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Insects & Arthropods (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Un antagonista peptídico aislado de Kv1.3 que tiene una secuencia de aminoácidos que comprende una secuencia de aminoácidos que es por lo menos un 84% idéntica a la SEQ ID NO: 1, que comprende además una sustitución de glicina por isoleucina en la posición (G10I).
ES14743871T 2013-01-25 2014-01-24 Antagonistas de Kv1.3 y métodos de uso Active ES2671434T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361756777P 2013-01-25 2013-01-25
US201361757389P 2013-01-28 2013-01-28
PCT/US2014/012932 WO2014116937A1 (en) 2013-01-25 2014-01-24 Kv1.3 antagonists and methods of use

Publications (1)

Publication Number Publication Date
ES2671434T3 true ES2671434T3 (es) 2018-06-06

Family

ID=51228060

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14743871T Active ES2671434T3 (es) 2013-01-25 2014-01-24 Antagonistas de Kv1.3 y métodos de uso

Country Status (29)

Country Link
US (2) US10179808B2 (es)
EP (1) EP2948559B1 (es)
JP (1) JP6469590B2 (es)
KR (1) KR102268830B1 (es)
CN (1) CN104937105A (es)
AU (1) AU2014209227B2 (es)
BR (1) BR112015017795A2 (es)
CA (1) CA2898496A1 (es)
CY (1) CY1120481T1 (es)
DK (1) DK2948559T3 (es)
EA (1) EA037308B1 (es)
ES (1) ES2671434T3 (es)
HR (1) HRP20181055T1 (es)
HU (1) HUE039465T2 (es)
IL (1) IL239927B (es)
LT (1) LT2948559T (es)
MX (1) MX365987B (es)
NZ (1) NZ709913A (es)
PH (1) PH12015501627B1 (es)
PL (1) PL2948559T3 (es)
PT (1) PT2948559T (es)
RS (1) RS57422B1 (es)
SG (1) SG11201505508TA (es)
SI (1) SI2948559T1 (es)
SM (1) SMT201800357T1 (es)
TR (1) TR201809377T4 (es)
UA (1) UA117824C2 (es)
WO (1) WO2014116937A1 (es)
ZA (1) ZA201506131B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015303825B2 (en) * 2014-08-15 2021-01-14 Baylor College Of Medicine Novel potassium channel blockers and use thereof in the treatment of autoimmune diseases
US10259122B2 (en) 2015-03-05 2019-04-16 President And Fellows Of Harvard College Compliant adaptive robot grasper
EP3452084A4 (en) 2016-05-02 2020-01-01 Tetragenetics, Inc. ANTI-KV1.3 ANTIBODIES AND METHOD FOR THE PRODUCTION AND USE THEREOF
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
TW201808987A (zh) * 2016-06-08 2018-03-16 健生生物科技公司 Ｇｍ－ｃｓｆ變體及使用方法
CN106589092A (zh) * 2016-12-22 2017-04-26 中国科学技术大学先进技术研究院 一种蝎毒素多肽及制备拥有类似天然生理功能的蝎毒素多肽的方法
CN106957357B (zh) * 2017-04-01 2021-02-19 合肥科生景肽生物科技有限公司 一种蝎毒素多肽及其合成方法
AU2019368816B2 (en) 2018-10-22 2025-01-30 Janssen Pharmaceutica Nv Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof
CA3155089A1 (en) * 2019-09-20 2021-03-25 Zealand Pharma A/S Kv1.3 blockers
BR112023019022A2 (pt) 2021-03-23 2023-10-17 Zealand Pharma As Bloqueadores de kv1.3
EP4604984A1 (en) 2022-10-18 2025-08-27 Zealand Pharma A/S Inhibitors
WO2026003546A1 (en) 2024-06-27 2026-01-02 Vrg Miniprotein Zrt Potassium ion kv1.3 channel inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1538206B1 (en) 1997-09-16 2010-03-24 Centocor, Inc. Method for the complete chemical synthesis and assembly of genes and genomes
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
GB0414272D0 (en) * 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
JP5118969B2 (ja) 2004-10-07 2013-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア Ｋｖ１．３カリウムチャネルの選択的阻害におけるＳｈＫトキシンの類似体ならびにその使用方法
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
AR063384A1 (es) * 2006-10-25 2009-01-28 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
EP2738257A1 (en) 2007-05-22 2014-06-04 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
EP2229473A4 (en) * 2007-12-07 2011-02-02 Steven A Goldstein IDENTIFICATION OF TOXIN LIGANDS
WO2010017632A1 (en) * 2008-08-13 2010-02-18 The University Of British Columbia Methods for stimulating chondrogenesis utilizing a potassium channel inhibitor
EP3385279B1 (en) 2009-03-20 2020-02-26 Amgen Inc. Carrier immunoglobulins and uses thereof
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules

Also Published As

Publication number Publication date
ZA201506131B (en) 2017-06-28
EP2948559B1 (en) 2018-05-02
BR112015017795A2 (pt) 2017-11-21
CA2898496A1 (en) 2014-07-31
NZ709913A (en) 2019-05-31
LT2948559T (lt) 2018-06-25
SI2948559T1 (en) 2018-08-31
MX2015009632A (es) 2015-11-30
JP6469590B2 (ja) 2019-02-13
US20140255401A1 (en) 2014-09-11
AU2014209227B2 (en) 2017-11-23
HUE039465T2 (hu) 2019-01-28
IL239927A0 (en) 2015-08-31
CY1120481T1 (el) 2019-07-10
PH12015501627A1 (en) 2015-09-21
DK2948559T3 (en) 2018-05-28
US20190062383A1 (en) 2019-02-28
EP2948559A1 (en) 2015-12-02
AU2014209227A1 (en) 2015-07-30
US10179808B2 (en) 2019-01-15
PL2948559T3 (pl) 2018-09-28
KR102268830B1 (ko) 2021-06-24
HRP20181055T1 (hr) 2018-09-07
TR201809377T4 (tr) 2018-07-23
EA037308B1 (ru) 2021-03-10
IL239927B (en) 2020-10-29
JP2016505639A (ja) 2016-02-25
SMT201800357T1 (it) 2018-09-13
PT2948559T (pt) 2018-07-24
CN104937105A (zh) 2015-09-23
WO2014116937A1 (en) 2014-07-31
SG11201505508TA (en) 2015-08-28
MX365987B (es) 2019-06-20
PH12015501627B1 (en) 2020-12-11
RS57422B1 (sr) 2018-09-28
EP2948559A4 (en) 2016-10-19
UA117824C2 (uk) 2018-10-10
KR20150108912A (ko) 2015-09-30
EA201591380A1 (ru) 2015-12-30

Similar Documents

Publication Publication Date Title
BR112015017795A2 (pt) antagonistas de kv1.3 e métodos de uso
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
MX2019011952A (es) Proteina anti-garp y sus usos.
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
TN2017000085A1 (en) Polypeptide having a polyester degrading activity and uses thereof
CO2017005995A2 (es) Composiciones para el cuidado bucal y métodos de uso
MX2017006866A (es) Pares de unión para producción de péptidos.
CL2017001070A1 (es) Variantes de interferon a2b
AR101742A1 (es) Agonista del receptor de calcitonina y amilina
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
EA201690280A1 (ru) Композиции и способы, относящиеся к выделенным эндофитам
EA201600474A1 (ru) Комбинированная терапия с использованием антитела к ang2 и агониста cd40
MX374811B (es) Anticuerpos anti-tau y métodos de uso.
MX2015004060A (es) 3-epimerasa.
EA201390820A1 (ru) Слитый белок против рака
BR112016024494A8 (pt) análogo de peptídeo e seu uso
WO2014139476A8 (zh) Rsv融合蛋白的表位以及识别其的抗体
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
UA115436C2 (uk) Протираковий злитий протеїн
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
EA201492068A1 (ru) Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии
MX370079B (es) Vacuna profilactica contra el sindrome de caida del huevo (eds).
WO2015198240A3 (en) Compositions and methods for long acting proteins
NZ724133A (en) Tfpi inhibitors and methods of use
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular